Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CHAPTER 3

Molecular Mimicry and Autoimmunity

Ramit Maoz-Segal†, Paulo Andrade†

†The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel
‡Infectious Diseases Department Hospital São João, Porto, Portugal
†Corresponding Author: ramitsegal@gmail.com

1 INTRODUCTION

The term molecular mimicry was originally defined by Damian as “the sharing of antigens between parasite and host”. The sequence similarity between foreign (a microorganism’s peptides) and self-peptides (the host’s antigen) enable pathogens that mimic self-epitopes to evade the immune system and lead to an immunological tolerance; in this way they gain an evolutionary advantage. The mechanism by which pathogens have evolved or obtained by chance similar amino acid sequences or the homologous three-dimensional crystal structure of immune-dominant epitopes remains a mystery, yet there are many examples of common microorganisms that ‘use’ this mechanism: the Vaccinia virus protein A49 mimics nuclear factor κB inhibitor; Neisseria meningitidis recruits complement-soluble plasma regulatory protein factor H by mimicking host carbohydrates; and group B Streptococcus (GBS) mimics host sialoglycan, resulting in impaired neutrophil function.

The phenomenon of molecular mimicry has, however, been just recently discovered as one of several ways in which autoimmunity can be evoked. Under certain circumstances, these infectious ‘mimickers’ can activate the immune system, initiate an immune response and lead to a breakdown in self-tolerance and autoimmunity. Structural homology – meaning that a single antibody or T-cell receptor can only be activated by a few residues – is crucial for this immune system activation. Following the encounter with the pathogen, activated autoreactive B or T cells can cross-react with self-epitopes, thus leading to autoimmunity. Autoimmunity is the result of a loss of immunological tolerance, the ability of the immunologic system to discriminate between self and nonself. Recent data show that autoimmune diseases affect approximately 1 in 31 people within the general population. Growth also has led to a greater characterisation of what autoimmunity is and how it
can be studied and treated. With the increased amount of research, there has been tremendous growth in the study of several different ways in which autoimmunity can occur, one of which is molecular mimicry. Thus, nowadays the term molecular mimicry has been transformed and is used to define an autoimmune response elicited by a microorganism’s antigenic determinants. 

Here we provide some examples of common infectious agents and their role in creating autoimmune disorders. Later, we present the opposite, describing autoimmune disorders in which there was found a relation to infectious agents via a molecular mimicry mechanism. At the end of each paragraph, the data are summarized in two tables.

2 COMMON INFECTIOUS AGENTS AND THEIR ROLL IN SETTING AUTOIMMUNE DISORDERS

2.1 Viruses

Epstein–Barr virus (EBV), a member of the herpesviridae family, is estimated to infect more than 90% of the human population. There is consistent evidence supporting the role of EBV in triggering many autoimmune diseases, particularly systemic lupus erythematosus (SLE). The most relevant mechanism by which EBV has been suggested to induce autoimmunity is molecular mimicry. Epstein–Barr nuclear antigen-1 (EBNA-1) has regions bearing homology to SLE-associated antigens such as ribonucleoprotein Smith antigen (Sm) and Ro self-protein. By tracing autoantibody response in SLE back in time, cross-reactivity was found between the Ro self-protein, the initial SLE autoantigen and EBNA-1, suggesting it is triggered by molecular mimicry. Furthermore, in mice, expression of EBNA-1 may elicit antibodies to Sm and double-stranded DNA (dsDNA), and antibodies elicited in response to EBNA-1 were shown to cross-react with dsDNA. Finally, in rabbits, immunization with EBNA-1 fragments containing the PPPGRRP sequence led to the development of antibodies with cross-reactivity to Sm and nuclear ribonucleoproteins; after immunization, most of the rabbits developed leucopenia or lymphopenia (or both), the features of which resemble those of SLE.

Cytomegalovirus (CMV), also a member of the herpesviridae family, is an extremely common human pathogen worldwide. Its role in triggering autoimmunity trough molecular mimicry has been pointed out in different autoimmune disorders. Immunoglobulin G antibodies from the sera of
patients with systemic sclerosis where found to recognize both autoantigens and human CMV late protein UL94 and to induce endothelial cell apoptosis.\textsuperscript{24} Cross-reactivity also was found between glutamic acid decarboxylase (a major autoantigen in diabetes mellitus type 1 and stiff-man syndrome) and CMV major DNA-binding protein pUL57, which supports the role of CMV in triggering those two pathologies.\textsuperscript{25} Regarding Guillain-Barré syndrome (GBS), it has been demonstrated that anti-GM2 antibodies cross-react with CMV-infected fibroblasts.\textsuperscript{26} Finally, Hsieh et al.\textsuperscript{27} demonstrated that most patients with SLE have antibodies to CMV phosphoprotein 65 when compared with controls and that immunization with CMV phosphoprotein 65 in mice elicited the production of antichromatin, antincen- triole, antimitotic spindle type I/II and anti-dsDNA antibody, as well as deposition of glomerular immunoglobulin.

Parvovirus B19 (PB19), a single-stranded DNA (ssDNA) virus and ubiquituous human pathogen, is the etiologic agent of erythema infectiosum (the fifth disease) and is responsible for such diverse pathologies as transient aplastic crisis, hydrops fetalis and arthropathy.\textsuperscript{28,29} Clinical resemblance of PB19 infection and some autoimmune disorders has raised the possibility of a link- age between the two.\textsuperscript{30,31} Loizou et al.\textsuperscript{32} compared sera of three groups of patients with acute PB19 infection, patients with other acute viral infections and patients with syphilis. He specified the antiphospholipid antibodies and further compared sera from those three groups with sera from patients with SLE trying to investigate the dependence of anticardiolipin binding on the presence of β2-glycoprotein I as a cofactor. Sera from patients with PB19 was found to have different antiphospholipid specificity when compared with sera from patients with other infections; like sera from patients with SLE trying but unlike sera from patients with other acute viral infections or syphilis, anticardiolipin antibodies of patients with PB19 were found to increase their binding ability in the presence of β2-glycoprotein I.\textsuperscript{32} After synthesizing a PB19 viral peptide, Lunardi et al.\textsuperscript{33} demonstrated that purified anti-PB19 antibodies cross-reacted with autoantigens such as keratin, collagen type II, ssDNA and cardiolipin. Afterwards, 8 mice were immunised with that same viral peptide, eliciting autoantibody production against keratin, collagen II, cardiolipin and ssDNA in 6 of them.\textsuperscript{33}

\subsection{2.2 Bacteria}

\textit{Streptococcus pyogenes}, a Gram-positive cocci, is the main etiologic agent of bacterial pharyngitis. One of the first and best established linkages between
a human pathogen and an autoimmune disorder was that of *S. pyogenes* and rheumatic fever (RF); molecular mimicry was proposed as trigger early on.\textsuperscript{34} Evidence of antibody cross-reactivity between the streptococcal M protein and cardiac myosin has been presented in different publications.\textsuperscript{35–37} Guilherme et al.\textsuperscript{38} demonstrated that T-cell clones from hearts of patients with RF recognized both streptococcal M protein and heart proteins. Regarding Sydenham chorea, cross-reactivity between mammalian lysoganglioside and *S. pyogenes* N-acetyl-beta-D-glucosamine was observed.\textsuperscript{39} Finally, Quinn et al.\textsuperscript{40} reported that 3 of 6 Lewis rats immunized with recombinant streptococcal M protein developed valvulitis and focal lesions of myocarditis, whereas Bronze and Dale\textsuperscript{41} showed that immunization of rabbits with streptococcal protein M elicited the production of antibodies with cross-reactivity to brain proteins, thus establishing a possible etiology for Sydenham chorea in patients with RF.

*Helicobacter pylori*, a Gram-negative bacillus estimated to infect about 50% of the world’s population, is linked with disorders such as atrophic gastritis, peptic ulcer disease and gastric carcinoma.\textsuperscript{42} Different autoimmune disorders have been associated with *H. pylori* infection, and molecular mimicry was proposed as a triggering mechanism in some of them. Appelmelk et al.\textsuperscript{43} observed that immunization of mice and rabbits with *H. pylori* lipopolysaccharide elicited production of antibodies to Lewis blood group antigens, which recognized human and murine gastric glandular tissue. Amedei et al.\textsuperscript{44} showed that cell clones of gastric T cells recovered from *H. pylori*-infected patients with autoimmune gastritis recognized both pathogen antigens and H\textsuperscript{+}, K\textsuperscript{+} ATPase. Finally, Takahashi et al.\textsuperscript{45} demonstrated that platelet-associated immunoglobulin G from the sera of patients with idiopathic thrombocytopenic purpura recognized *H. pylori* CagA protein.

*Campylobacter jejuni*, a Gram-negative, spiral-shaped bacillus, is one of the most common agents of bacterial gastroenteritis in the world.\textsuperscript{46} Postinfectious GBS is one of the best examples of autoimmune disease triggered by bacterial infection; up to a third of cases are preceded by *C. jejuni* infection.\textsuperscript{47} Structural homology between *C. jejuni* lipo-oligosaccharide (LOS) and human ganglioside GM1 was first demonstrated by Yuki et al.\textsuperscript{48} and Willison and Yuki;\textsuperscript{49} later, cross-reactivity between *C. jejuni* LOS and human antiganglioside antibodies was observed. Furthermore, animal studies have shown anti-GM1 antibody development and neurologic disorders resembling GBS upon immunization with *C. jejuni* LOS, thus supporting the role of molecular mimicry in this disease.\textsuperscript{50}
2.3 Parasites

Trypanosoma cruzi, a flagellated protozoan parasite, is the etiologic agent of Chagas’ disease, a disorder with protean clinical manifestations including digestive, nervous and cardiac involvement; the latter is the most important because of its frequency and clinical implications.\textsuperscript{51–55} The contribution of molecular mimicry in triggering Chagas’ disease cardiopathy has been suggested by a number of publications.\textsuperscript{56,57} Immunization of mice with cruzipain, a parasitic antigen, elicited anticruzipain and antimyosin antibody production and was associated with heart conduction disturbances.\textsuperscript{58} Cunha-Neto et al.\textsuperscript{59,60} demonstrated cross-reactivity between a heart-specific epitope of myosin and \textit{T. cruzi} antigen B13 and further identified simultaneous responsiveness of heart-infiltrating T-cell clones from patients with Chagas’ disease cardiopathy to cardiac myosin heavy chain and \textit{T. cruzi} antigen B13. Leon et al.\textsuperscript{61,62} showed that mice immunized with \textit{T. cruzi} protein extract emulsified in complete Freund’s adjuvant developed antibodies and delayed-type hypersensitivity to cardiac myosin, whereas mice immunized with cardiac myosin developed antibodies and delayed-type hypersensitivity to \textit{T. cruzi}. Induction of peripheral immune tolerance to \textit{T. cruzi} or myosin led to a decrease in cellular immunity to myosin and \textit{T. cruzi}, respectively. Finally, mice immunized with R13 synthetic peptide, corresponding to sequences in the \textit{T. cruzi} ribosomal P1 and P2 proteins, generated antibodies to R13 as well as to H3, an autoantigen, followed by cardiac structure abnormalities.\textsuperscript{63} (Table 1).

Autoimmunity is believed to be the consequence of a breakdown in self-tolerance that induces an attack of the immune system on different organs and tissues. A combination of genetic, immunologic and environmental factors is required, comprising what is nowadays called ‘the mosaic of autoimmunity’.\textsuperscript{79}

Microbial antigens have the potential to initiate autoreactivity through molecular mimicry and other mechanisms such as polyclonal activation or the release of previously sequestered antigens.\textsuperscript{80} Although the triggering event in most autoimmune diseases is unknown, the process of molecular mimicry between microbial and self-components (e.g., proteins, carbohydrates or DNA epitopes) is postulated to be the most likely mechanism of postinfectious autoimmunity.

Molecular mimicry is one mechanism by which infectious agents (or other exogenous substances) may trigger an immune response against auto-antigens. According to this hypothesis, a susceptible host acquires an
| Pathogen          | Associated autoimmune disorder | Mimicking pathogenic antigen | References |
|-------------------|--------------------------------|-----------------------------|------------|
| **Virus**         |                                |                             |            |
| CMV               | DM1                            | pUL94                       | 24         |
| SS                | pUL57                          |                             | 25         |
| APS               | TIFI                           |                             | 64         |
| EBV               | MS                             | LMP-1                       | 65         |
| SLE               | EBNA-1                         |                             | 16–22      |
| RA                | BZLF-1, BMLF-1                 |                             | 66         |
| Enterovirus       | DM1                            | Several viral peptides      | 67         |
| HBV               | MS                             | HBV DNA polymerase          | 68         |
| HCV               | AH                             | Core protein                | 69         |
| HIV               | AT                             | Core protein                | 70         |
| HSV               | SLE                            | HCV polyprotein             | 71         |
| PB19              | MG                             | p24 Capsid antigen          | 72         |
| Rubella           | DM1                            | p24 Capsid antigen          | 72         |
| **Bacteria**      | GBS                            | Glycoprotein D              | 73         |
| Campylobacter jejuni |                 | VP1u                        | 74         |
| Clostridium tetani (toxoid) |         | Several viral peptides      | 75         |
| Chlamydia trachomatis |             |                             |            |
| Hemophilus influenzae |             |                             |            |
| Helicobacter pylori | AG                  | LOS                        | 48–50      |
| Clostridium tetani (toxoid) |     | TLRVYK hexapeptide          | 76         |
| Chlamydia trachomatis | AS                  | DNA primase                | 77         |
| Hemophilus influenzae | MS              | Protease IV                | 73         |
| Helicobacter pylori | AG                  | TLRVYK hexapeptide          | 76         |
| Neisseria gonorrhoeae | APS             | LPS                        | 43         |
| Helicobacter pylori | ITP                | CagA                       | 45         |
| Streptococcus pyogenes | RF               | TLRVYK hexapeptide          | 76         |
| Parasites         | Trypanosoma cruzi             |                             |            |
| CD                | Cruzipain                     |                             | 58         |
| B13               | N-acetyl-β-D-glucosamine      |                             | 39         |
| R13 synthetic peptid |                     |                             | 63         |

AG, autoimmune gastritis; AH, autoimmune hepatitis; APS, antiphospholipid syndrome; AS, ankylosing spondylitis; AT, autoimmune thyroiditis; CD, Chagas disease; CMV, cytomegalovirus; CryG, cryoglobulinemia; DM1, type 1 diabetes mellitus; EBV, Epstein-Barr virus; GBS, Guillain–Barré syndrome; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; ITP, idiopathic thrombocytopenic purpura; LOS, lipo-oligosaccharide; LPS, lipopolysaccharide; MG, myasthenia gravis; MS, multiple sclerosis; PB19, parvovirus B19; RA, rheumatoid arthritis; RF, rheumatic fever; SLE, systemic lupus erythematosus; SjS, Sjogren’s syndrome; SS, systemic sclerosis.
infection with an agent that has antigens that are immunologically similar to the host antigens but differ sufficiently to induce an immune response when presented to T cells. As a result, the tolerance to autoantigens breaks down, and the pathogen-specific immune response that is generated cross-reacts with host structures to cause tissue damage and disease. This model has persisted for more than three decades because it offers an attractive conceptual link between physiologic responses (defence against infection) and a pathologic process (autoimmunity).

Cross-reactivity between foreign (i.e., infectious) and self-antigens can be determined by different methods. One approach is to enable the detection of cross-reactive self-antigens and humoral response by identifying a suspected causative organism and its antigenic epitopes. Another method, when the causative organism is unknown, is identifying T-cell determinants capable of inducing autoimmunity and then searching for homologous microbial sequences that might activate the immune system in a major histocompatibility complex–dependent way.81

In recent years, the role of different infectious agents has been extensively studied, and several mechanisms were found to be associated with postinfectious autoimmunity pathogenesis, of which molecular mimicry is the dominant mechanism.82 For example, it was found that several human monoclonal antibodies can react specifically with infectious agents as well as with human antigens.83 These antibodies are believed to be at least partially responsible for initiating a pathogenic process that eventually results in autoimmunity. Those studies led to the suggested criteria for ‘diagnosing’ the role of molecular mimicry in autoimmune diseases.50 The first requirement is that the suspected pathogen must be associated with the presence, onset or exacerbation of the autoimmune disease in a convincing number of patients. Second, the infectious agent must provoke either a T-cell-dependent or T-cell-independent immune response (i.e., autoantibodies) that cross-reacts with host antigens and is clinically relevant to the autoimmune disease. The proof of the causality between the mimic epitope and the autoimmune disease can be achieved by active immunization with the shared epitope in animal models and induction of the autoimmune disease or by passive transfer of the disease using autoreactive T cells or autoantibodies.

In conclusion, molecular mimicry has been linked to the pathogenesis of many autoimmune diseases. Here we review a few major examples of different autoimmune diseases that have been linked to this mechanism. The data of these examples as well as other autoimmune diseases and related
infectious agents that were found to be escaping the immune system through the role of molecular mimicry are summarized in Table 2.

### 3 NEURO-AUTOIMMUNE DISEASE

Multiple sclerosis is a chronic human autoimmune disease characterized by mononuclear cell infiltration and demyelization within the central nervous system (CNS) and neurological dysfunction. In the case of multiple sclerosis, it has been hypothesized that the disease is initiated by an infection early in life by a virus that shares antigenic structures with the host’s CNS tissue. The host immune response against EBV, influenza virus type A and human papillomavirus peptides cross-reacts with CNS self-antigens, such as myelin basic protein, leading to demyelization. Subsequent viral infections are thought to cause exacerbations of the disease by reactivating the immune response against viral antigens and autoantigens.99

### 4 ENDOCRINOLOGICAL AUTOIMMUNE DISEASE

Insulin-dependent diabetes mellitus (IDDM), or type I diabetes, is an autoimmune disease involving mononuclear cell infiltration of the pancreatic islets (insulitis), destruction of the beta islet cells and insulin deficiency. In autoimmune diabetes, T cells recognize both a peptide derived from the autoantigen glutamic-acid decarboxylase and a highly analogous peptide from the coxsackievirus P2-C protein (see Table 2).

### 5 INFLAMMATORY ARTICULAR DISEASE

Rheumatoid arthritis (RA) is a human autoimmune disease with an unknown etiology and is characterized by symmetrical persistent inflammatory synovitis of the peripheral joints. Rheumatic fever (RF) is the classical example of molecular mimicry resulting in postinfectious autoimmunity. A timely association between streptococcal infection and RF had been demonstrated in the majority of patients. Streptococcal epitopes such as N-acetylglucosamine or M-protein mimic cardiac myosin and α-helical proteins present in the valve, whereas N-acetyl glucosamine also mimics neuronal ganglioside. T-cell clones originating from human RF heart lesions recognize bacterial M-protein peptides and heart-derived peptides. These mimic peptides are clearly associated with major manifestations of RF that affect the heart valves and neuronal elements, among other organs.100,39
| Autoimmune Disorder | Self-antigen | Pathogen | References |
|----------------------|-------------|----------|------------|
| Rheumatic fever      | Cardiac myosin, tropomyosin, laminin, vimentin, actin, keratin, N-acetyl-glucosamine | *Streptococcus pyogenes* M protein and N-acetyl-glucosamine | 84–86 |
| Chagas cardiomyopathy | Human β1-adrenergic receptor, cardiac myosin, Cha antigen, common glycolipid antigen on nervous tissue | *Trypanosoma cruzi* ribosomal PO, B13 protein, shed acute-phase antigen (SAPA); 160-kDa flagellum; trypomastigote stage specific glycoprotein | 58 |
| Rheumatoid arthritis | BZLF1, BMLF1 | EBV | 13,66 |
| Ankylosing spondylitis | HLA B27 | Klebsiella pneumonia, chlamydia | 87 |
| Systemic lupus erythematosus | Ro 60 kD, Sm, MDA, dsDNA | Mycobacteria, Klebsiella pneumonia Pneumococcal polysaccharide EBV, HERV, Coxsackie virus 2B, parvovirus, retroviruses | 13,88–93 |
| Sjögren’s syndrome | Ro 60 kD | Coxsackie virus 2B | 94 |
| Antiphospholipid syndrome | β2 Glycoprotein I | Hemophilus influenza, Niesseria gonorrhoeae, tetanus toxin, parvovirus B12, CMV | 64,76 |
| Autoimmune liver diseases | Core protein | HCV | 69,70 |
| Inflammatory bowel diseases | Cruzipain | *Trypanosoma cruzi* | 58 |
| Type I diabetes mellitus | pUL94, viral peptides | CMV, enterovirus, rubella | 67,75 |
| Autoimmune thyroid diseases | HCV polyprotein | HCV | 71 |

Continued
### Table 2 Molecular mimicry mechanism in different autoimmune disorders—cont’d

| Autoimmune Disorder | Self-antigen                                                                 | Pathogen                                                                 | References  |
|---------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------|
| Multiple sclerosis  | Myelin basic protein Myelin oligodendrocyte glycoprotein 18–32              | Corona virus, measles, mumps, EBV, human herpes Semliki Forest virus E2 peptide 115–129, *Acanthamoeba castellanii*, influenza virus type A, human papillomavirus | 95,88,96,13 |
| Myasthenia gravis   | Acetylcholine receptor neurofilaments                                         | Herpes virus, hemophilus influenza                                         | 97          |
| Guillain-Barré syndrome | Gangliosides                                                                  | *Campylobacter jejuni* lipo-oligosaccharide                               | 98          |

CMV, cytomegalovirus; dsDNA, double-stranded DNA; EBV, Epstein-Barr virus; HCV, hepatitis C virus; HERV, human endogenous retrovirus; HLA, human leukocyte antigen; MDA, malondialdehyde; Sm, Smith.
Moreover, active immunization with these cross-reactive peptides induces myocarditis in mice, and passive transfer of purified antibodies from rats immunised with cardiac myosin resulted in immunoglobulin G deposition and apoptosis, leading to cardiomyopathy.\textsuperscript{101,102}

6 VASCULITIDES

SLE is a multisystem human autoimmune disease characterized by multiple autoantibodies: anti-dsDNA, anti-Ro/La, antiribonucleoprotein complex, antihistone and other nuclear components. Among autoimmune diseases, SLE was linked to several viral and bacterial agents, especially the EBV, which is a ubiquitous pathogen associated with many autoimmune diseases. The interaction between EBV and SLE is not unidirectional. EBV may trigger autoimmunity (the appearance of SLE-associated autoantibodies and clinical manifestations), but it can also affect the immunologic system in patients with SLE, who seem to have an impaired anti-EBV immune response and dysregulation of the viral latency period compared with controls.\textsuperscript{103,104} In recent years, several other viruses have been linked to SLE as well, and molecular mimicry was suggested as the responsible mechanism. For the majority of them, however, only antigenic cross-reactivity had been demonstrated so far. The first example for cross-reactivity is the peptide derivative from Coxsackie virus 2B protein (pepCoxs), which has 87% amino acid homology with the 222–229 region of the major linear antibody binding site of the Ro 60-kD autoantigen. The Coxsackie virus was suggested to have a potential role in the autoimmune response against Ro/SSA and La/SSB as well.\textsuperscript{94} The second example of cross-reactivity is the PB19, which has been implicated as a causative agent of several autoimmune disorders, including SLE. A peptide that shares homology with the parovirus VP1 protein and with human cytokeratin (the transcription factor GATA1) and that plays an essential role in megakaryopoiesis and erythropoiesis was identified and was suggested to have a role in the induction of cross-reactive autoantibodies.\textsuperscript{88} Furthermore, endogenous retrovirus elements and nonendogenous elements were found to be linked with autoimmunity, and molecular mimicry between those retroviruses and a host antigen was proposed.\textsuperscript{89} The complex interplay between infections, genetics and autoimmunity regarding retroviruses in SLE patients is reviewed elsewhere.\textsuperscript{90}

A molecular mimicry mechanism in lupus was studied in bacterial infections as well (i.e., mycobacteria, Klebsiella pneumonia), mainly with
anti-dsDNA antibodies, and has been documented in animal models and in humans.\textsuperscript{91,105} For example, in healthy individuals, elevated titers of anti-dsDNA antibodies can be detected following different bacterial infections.\textsuperscript{92} Furthermore, sera from patients infected with the Gram-negative pathogen \textit{Klebsiella pneumoniae} were found to have high titers of a common anti-DNA idiotype (16/6ID). Another example is the similarity found between the B 561 peptides from \textit{Burkholderia} bacteria and anti-dsDNA antibodies.\textsuperscript{106} The cross-reactivity between anti-dsDNA and \textit{Burkholderia} peptides points to the possible role of bacterial infection in inducing the production of autoantibodies.

6.1 Summary and Suggestions for the Future: ‘Control’ of Molecular mimicry

The complex causes of autoimmune diseases not only present a challenge to the development and testing of new therapies but also offer a framework that allows the identification of subgroups of patients who might benefit from particular approaches. Molecular mimicry is one of the most logical explanations for the linkage between infection and autoimmunity, and its concept is a useful tool in understanding the etiology and pathogenesis of autoimmune disorders. The examples detailed in this chapter supply evidence for the role of specific pathogens in triggering particular autoimmune disorders by molecular mimicry. However, a definite direct causality between this mechanism and autoimmunity is yet to be established.

Understanding the mechanism of molecular mimicry in autoimmune disorders, one cannot avoid thinking that autoimmunity caused by molecular mimicry can be avoided. Control of the initiating factor (pathogen) via vaccination seems to be the most common method of avoiding autoimmunity. Inducing tolerance to the host autoantigen in this way may also be the most stable factor. The development of a downregulating immune response to the epitopes shared between the pathogen and the host may be the best way of treating an autoimmune disease caused by molecular mimicry.\textsuperscript{107} Unfortunately, this method is not straightforward. Recently, a large number of published case reports of immunologic late reactions to vaccines raised the hypothesis that specific vaccines containing adjuvants are responsible for autoimmune diseases, especially in genetically susceptible patients. The entity autoimmune/auto-inflammatory syndrome induced by adjuvants describes the role of various environmental factors in the pathogenesis of immune-mediated diseases. Of these factors, those entailing immune adjuvant activity, such as infectious agents, silicone, aluminium salts and others,
were associated with defined and nondefined immune-mediated diseases both in animal models and in humans.\textsuperscript{108}

Understanding the mechanisms of molecular mimicry may allow future research to be directed towards uncovering the initiating infectious agent as well as recognizing the self-determinant. Willingly, future research may be able to design strategies for the treatment and prevention of autoimmunity.

\textbf{REFERENCES}

1. Damian RT. Molecular mimicry; antigen sharing by parasite and host and its consequences. \textit{Am Nat} 1964;\textbf{98}(900):129–49.
2. Damian RT. Parasite immune evasion and exploitation: reflections and projections. \textit{Parasitology} 1997;\textbf{115}(Suppl):S169–75.
3. Würzner R. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. \textit{Mol Immunol} 1999;\textbf{36}(4–5):249–60.
4. Elde NC, Malik HS. The evolutionary conundrum of pathogen mimicry. \textit{Nat Rev Microbiol} 2009;\textbf{7}(11):787–97.
5. Mansur DS, Maluquer de Motes C, Unterholzner L, Sumner RP, Ferguson BJ, Ren H, et al. Poxvirus targeting of E3 ligase β-TrCP by molecular mimicry: a mechanism to inhibit NF-κB activation and promote immune evasion and virulence. \textit{PLoS Pathog} 2013;\textbf{9}(2):e1003183.
6. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. \textit{Nature} 2009;\textbf{458}(7240):890–3.
7. Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. \textit{Blood} 2009;\textbf{113}(14):3333–6.
8. Agmon–Levin N, Blank M, Paz Z, Shoenfeld Y. Molecular mimicry in systemic lupus erythematosus. \textit{Lupus} 2009;\textbf{18}(13):1181–5.
9. Kohm AP, Fuller KG, Miller SD. Mimicking the way to autoimmunity: an evolving theory of sequence and structural homology. \textit{Trends Microbiol} 2003;\textbf{11}(3):101–5.
10. Shoenfeld Y, Gershwin ME. Autoimmunity at a glance. \textit{Autoimmun Rev} 2002;\textbf{1}.
11. Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto–immunity. \textit{Clin Rev Allergy Immunol} 2007;\textbf{32}(1):111–18.
12. Cohen JI. Epstein–Barr virus infection. \textit{N Engl J Med} 2000;\textbf{343}(7):481–92.
13. Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein–Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. \textit{Ann N Y Acad Sci} 2007;\textbf{108}(7):567–77.
14. Berkun Y, Zandman–Goddard G, Barzilai O, Boaz M, Sherer Y, Larida B, et al. Infectious antibodies in systemic lupus erythematosus patients. \textit{Lupus} 2009;\textbf{18}(13):1129–35.
15. Zandman–Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, et al. Exposure to Epstein–Barr virus infection is associated with mild systemic lupus erythematosus disease. \textit{Ann N Y Acad Sci} 2009;\textbf{1173}:658–63.
16. Sabbatini A, Bombardieri S, Migliorini P. Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein–Barr virus–encoded nuclear antigen EBNA I. \textit{Eur J Immunol} 1993;\textbf{23}:1146–52.
17. McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. \textit{J Immunol} 2002;\textbf{168}:2054–62.
18. James JA, Scofield RH, Harley JB. Lupus humoral autoimmunity after short peptide immunization. *Ann N Y Acad Sci* 1997;815:124–7.

19. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. *Nat Med* 2005;11(1):85–9.

20. Sundar K, Jacques S, Gottlieb P, Villars R, Benito ME, Taylor DK, et al. Expression of the Epstein-Barr virus nuclear antigen–1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. *J Autoimmun* 2004;23(2):127–40.

21. Yadav P, Tran H, Ebegbe R, Gottlieb P, Wei H, Lewis RH, et al. Antibodies elicited in response to EBNA-1 may cross-react with dsDNA. *PLoS One* 2011;6(1):e14488.

22. Poole BD, Gross T, Maier S, Harley JB, James JA. Lupus–like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. *J Autoimmun* 2008;31(4):362–71.

23. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev Med Virol* 2010;20(4):202–13.

24. Lunardi C, Bason C, Navone R, Millo E, Damonte G, Corrocher R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. *Nat Med* 2000;6(10):1183–6.

25. Hemstra HS, Schloot NC, van Veelen PA, Willemen SJ, Franken KL, van Rood JJ, et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. *Proc Natl Acad Sci U S A* 2001;98(7):3988–91.

26. Ang CW, Jacobs BC, Brandenburg AH, Laman JD, van der Meche FG, Osterhaus AD, et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. *Neurology* 2000;54(7):1453–8.

27. Hsieh AH, Jhou YJ, Liang CT, Chang M, Wang SL. Fragment of tegument protein pp65 of human cytomegalovirus induces autoantibodies in BALB/c mice. *Arthritis Res Ther* 2011;13(5):R162.

28. Mossong J, Hens N, Friederichs V, Davidkin I, Broman M, Litwinska B, et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. *Epidemiol Infect* 2008;136(8):1059–68.

29. Sabella C, Goldfarb J. Parvovirus B19 infections. *Am Fam Physician* 1999;60(5):1455–60.

30. Lehmann HW, Von Landenberg P, Modrow S. Parvovirus B19 infection and autoimmune disease. *Autoimmun Rev* 2003;2(4):218–23.

31. Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. *Lupus* 2010;19(7):783–92.

32. Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. *Arthritis Rheum* 1997;40(1):103–8.

33. Lunardi C, Tiso M, Borgato L, Nanni L, Millo R, De Sandre G, et al. Chronic parvovirus B19 infection induces the production of anti–virus antibodies with autoantigen binding properties. *Eur J Immunol* 1998;28(3):936–48.

34. Zabriskie JB. Mimetic relationships between group A streptococci and mammalian tissues. *Adv Immunol* 1967;7:147–88.

35. Dale JB, Beachey EH. Epitopes of streptococcal M proteins shared with cardiac myosin. *J Exp Med* 1985;162(2):583–91.

36. Cunningham MW, McCormack JM, Fenderson PG, Ho MK, Beachey EH, Dale JB. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-GLN in M protein. *J Immunol* 1989;143(8):2677–83.
37. Quinn A, Ward K, Fischetti VA, Henric M, Cunningham MW. Immunological relationship between the class I epitope of streptococcal M protein and myosin. *Infect Immun* 1998;66(9):4418–24.

38. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pomerantzef PM, Assis RV, et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. *Circulation* 1995;92(3):415–20.

39. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. *Nat Med* 2003;9(7):914–20.

40. Quinn A, Kosanke S, Fischetti VA, Factor SM, Cunningham MW. Induction of autoimmune valvular heart disease by recombinant streptococcal protein. *Infect Immun* 2001;69(6):4072–8.

41. Bronze MS, Dale JB. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. *J Immunol* 1993;151(5):2820–8.

42. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. *Aliment Pharmacol Ther* 2002;16(Suppl 1):3–15.

43. Appelmelk BJ, Simoons-Smit I, Negrini R, Moran AP, Aspinall GO, Forte JG, et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. *Infect Immun* 1996;64(6):2031–40.

44. Amedei A, Bergman MP, Appelmelk BJ, Azzurri A, Benagiano M, Tamburini C, et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+ −adenosine triphosphatase in human gastric autoimmunity. *J Exp Med* 2003;198(8):1147–56.

45. Takahashi T, Yujiri T, Shinohara K, Inoue Y, Sato Y, Fujii Y, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. *Br J Haematol* 2004;124(1):91–6.

46. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. *Clin Infect Dis* 2001;32(8):1201–6.

47. Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. Guillain-Barré syndrome—a classical autoimmune disease triggered by infection or vaccination. *Clin Rev Allergy Immunol* 2012;42(2):121–30.

48. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. *J Exp Med* 1993;178(5):1771–5.

49. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. *Brain* 2002;125(Pt 12):2591–625.

50. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipopoligosaccharide causes Guillain-Barre syndrome. *Proc Natl Acad Sci U S A* 2004;101(31):11404–9.

51. Chagas C. Nova tripanozomiasi humana. Estudos sobre a morfologia e o ciclo evolutivo do *Schizotrypanum cruzi* n. gen. n. sp., agente etiológico de uma nova entidade morbida do homem. *Mem Inst Oswaldo Cruz* 1909;1:159–218.

52. Chagas C. Tripanosomiase americana. Forma aguda da moléstia. *Mem Inst Oswaldo Cruz* 1916;8:37–60.

53. Chagas C. Processos patojênicos da Tripanozomiasi Americana. *Mem Inst Oswaldo Cruz* 1916;8:5–36.

54. Chagas C. Villela E. Forma cardíaca da Trypanosomiase Americana. *Mem Inst Oswaldo Cruz* 1922;14:5–61.

55. Prata A. Clinical and epidemiological aspects of Chagas disease. *Lancet Infect Dis* 2001;1(2):92–100.
56. Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. *Autoimmunity* 2006;39(1):41–54.

57. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? *Curr Mol Med* 2008;8(6):510–18.

58. Giordanengo L, Maldonado C, Riverola HW, Iosa D, Girones N, Fresno M, et al. Induction of antibodies reactive to cardiac myosin and development of heart alterations in cruzipain-immunized mice and their offspring. *Eur J Immunol* 2000;30(11):3181–9.

59. Cunha-Neto E, Duranti M, Gruber A, Zingales B, De Messias I, Stolf N, et al. Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin–specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. *Proc Natl Acad Sci U S A* 1995;92(8):3541–5.

60. Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, Kalil J. Autoimmunity in Chagas’ disease. Identification of cardiac myosin–B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas’ cardiomyopathy patient. *J Clin Invest* 1996;98(8):1709–12.

61. Leon JS, Daniels MD, Toriello KM, Wang K, Engman DM. A cardiac myosin-specific autoimmune response is induced by immunization with Trypanosoma cruzi proteins. *Infect Immun* 2004;72(6):3410–17.

62. Leon JS, Wang K, Engman DM. Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas’ disease. *J Immunol* 2003;171(8):4271–7.

63. Motrán CC, Fretes RE, Cerbán FM, Riverola HW. Voltoto de Cima E. Immunization with the C-terminal region of Trypanosoma cruzi ribosomal P1 and P2 proteins induces long-term duration cross-reactive antibodies with heart functional and structural alterations in young and aged mice. *Clin Immunol* 2000;97(2):89–94.

64. Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Anti-phospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. *Arthritis Rheum* 2002;46(2):545–52.

65. Gabibov AG, Belogurov Jr AA, Lomakin YA, Zakharova MY, Avakyan ME, Dubrovskaya VV, et al. Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. *FASEB J* 2011;25(12):4211–21.

66. Scotet E, David-Ameline J, Peyrat MA, Moreau-Aubry A, Pinczon D, Lim A, et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. *J Exp Med* 1996;184(5):1791–800.

67. Härkönen T, Lankinen H, Davydova B, Hovi T, Roivainen M. Enterovirus infection can induce immune responses that cross-react with beta-cell autoantigen tyrosine phosphatase IA2–IA/R. *J Med Virol* 2002;66(3):340–50.

68. Fujinami RS, Oldstone MB. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. *Science* 1985;230(4729):1043–5.

69. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KM, Reichen J, et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. *J Exp Med* 1999;190(2):169–76.

70. Hartmann H, Schott P, Polzien F, Mihm S, Uy A, Kaboth U, et al. Cryoglobulinemia in chronic hepatitis C virus infection: prevalence, clinical manifestations, response to interferon treatment and analysis of cryoprecipitates. *Z Gastroenterol* 1995;33(11):643–50.

71. Muratori L, Bogdanos DP, Muratori P, Lenzi M, Granato A, Ma Y, et al. Susceptibility to thyroid disorders in hepatitis C. *Clin Gastroenterol Hepatol* 2005;3(6):595–603.

72. Deas JE, Liu LG, Thompson JJ, Sander DM, Soble SS, Garry RF, et al. Reactivity of sera from systemic lupus erythematosus and Sjögren’s syndrome patients with peptides
derived from human immunodeficiency virus p24 capsid antigen. Clin Diagn Lab Immunol 1998;5(2):181–5.

73. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MB. Molecular mimicry and myasthenia gravis An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989;84(4):1174–80.

74. Tzang BS, Lee YJ, Yang TP, Tsay GJ, Shi JY, Tsai CC, et al. Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta 2007;382(1–2):31–6.

75. Ou D, Mitchell LA, Metzger DL, Gillam S, Tingle AJ. Cross-reactive rubella virus and glutamic acid decarboxylase (65 and 67) protein determinants recognised by T cells of patients with type I diabetes mellitus. Diabetologia 2000;43(6):750–62.

76. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109(6):797–804.

77. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, López de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002;277(40):37573–81.

78. Van Voorhis WC, Schlekey WS, Trong HL. Molecular mimicry by Trypanosoma cruzi: the F1-160 epitope that mimics mammalian nerve can be mapped to a 12-amino acid peptide. Proc Natl Acad Sci U S A 1991;88(14):5993–7.

79. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune disease—2008. Isr Med Assoc J 2008;10:8–12.

80. Macray Ian R, Rosen Fred S. autoimmune disease. N Engl J Med 2001;345(5):340–50.

81. Lim DG, Haffler DA. Molecular mimicry in multiple sclerosis: role of MHC altered peptide Ligands. In: Infections and autoimmunity. 1st ed. Amsterdam: Elsevier; 2004. p. 45–55.

82. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998;12:1255–65.

83. Srinivasappa J, Saegusa J, Prabhakar BS, et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral Abs with normal tissues. J Virol 1986;57:397–401.

84. Galvin JE, Henric ME, Ward K, Cunningham MW; Cytotoxic mAb from rheumatic carditis recognizes hert valve and laminin. J Clin Invest 2000;106:217–24.

85. Guilhrme I, Cunha-Neto E. Coelho V et el; Human heart—infiltrating T cells clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995;92:415–20.

86. Malkiel S, Liao L, Cunningham MW, Diamond B. T–cell dependant ride, N-acetylglucosamines, is cross-reactive with cardiac myosin. Infect Immun 2000;68:5803–8.

87. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, de Castro JA López. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002;277(40):37573–81.

88. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008;8:116–20.

89. Perl A, Nagy G, Koncz A, et al. Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity 2008;41:287–97.

90. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009;18(13):1136–43.

91. Shoenfeld Y, Vilner Y, Coates AR, et al. Monoclonal anti-tuberculosis Abs react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol 1986;66:255–61.
92. Zandman-Goddard G, Shoenfeld Y. SLE and infections. In: Infections and autoimmunity. 1st ed. Amsterdam: Elsevier; 2004. p. 491–503.
93. Zhang W, Reichlin M. A possible link between infection with burkholderia bacteria and systemic lupus erythematosus based on epitope mimicry. Clin Dev Immunol 2008;1–7.
94. Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AG. Cross-reaction between Abs to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein. Clin Exp Immunol 2005;141:148–54.
95. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695–705.
96. Lang HLE, Jacobsen H, Ikemizu S, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:940–3.
97. Peter LS, Thomas D, Daniel BD, Michael BA, Oldstone MB. Molecular Mimicry and Myasthenia Gravis, An Autoantigenic Site of the Acetylcholine Receptor a-Subunit That Has Biologic Activity and Reacts Immunohchemically with Herpes Simplex Virus. J Clin Invest 1989;84(4):1174–80.
98. Yuki N. Pathogenesis of Guillan Barre and Miller Fisher syndromes subsequent to campylobacter jejuni enteritis. Jpn J Infect Dis 1999;52:99–105.
99. Lori JA, Iman Robert D. Molecular mimicry and autoimmunity. NEJM 1999;341(27):2068–74.
100. Guilherme L, Kalil J, Cunningham MW. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006;39:31–9.
101. Cunningham MW. Streptococcus-induced myocarditis in mice. Autoimmunity 2001;34:193–7.
102. Li Y, Heuser JS, Cunningham LC, et al. Mimicry and antibodymediated cell signaling in autoimmune myocarditis. J Immunol 2006;177:8234–40.
103. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein–Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008;41:298–328.
104. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and systemic lupus erythematosus: a new perspective. J Immunol 2005;174:6599–607.
105. George J, Shoenfeld Y. Infections, idiotypes and SLE. Lupus 1995;4:333–5.
106. Zhang W, Reichlin M. A possible link between infection with burkholderia bacteria and systemic lupus erythematosus based on epitope mimicry. Clin Dev Immunol 2008;2008(683489):1–7.
107. Barnett LA, Fujinami RS. Molecular mimicry: a mechanism for autoimmunity. FASEB J 1992;6:840–4.
108. Shoenfeld Y, Agmon-Levin N. ’ASIA’–autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011;36(1):4–8.